Prasugrel hydrochloride, dronedarone, and saxagliptin hydrochloride.
作者信息
Hussar Daniel A
机构信息
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
出版信息
J Am Pharm Assoc (2003). 2009 Nov-Dec;49(6):832-6. doi: 10.1331/JAPhA.2009.09544.
PMID:19926567
Abstract
摘要
相似文献
1
Prasugrel hydrochloride, dronedarone, and saxagliptin hydrochloride.
J Am Pharm Assoc (2003). 2009 Nov-Dec;49(6):832-6. doi: 10.1331/JAPhA.2009.09544.
2
New advances and new questions in cardiovascular therapeutics.
Am J Ther. 2009 Sep-Oct;16(5):375-7. doi: 10.1097/MJT.0b013e3181b95ff6.
3
Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Ann Pharmacother. 2010 Jun;44(6):1046-53. doi: 10.1345/aph.1P003. Epub 2010 May 11.
4
Saxagliptin and tuberculosis.
Prescrire Int. 2013 Jan;22(134):17.
5
Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?
Int J Cardiol. 2016 Oct 1;220:573-4. doi: 10.1016/j.ijcard.2016.06.269. Epub 2016 Jun 29.
6
No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Metab Syndr Relat Disord. 2014 Apr;12(3):157-8. doi: 10.1089/met.2014.1500. Epub 2014 Feb 12.
7
Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Expert Opin Pharmacother. 2009 Dec;10(17):2927-34. doi: 10.1517/14656560903456046.
8
Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
Cardiovasc J Afr. 2013 Aug;24(7):290.
9
Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
IDrugs. 2008 Dec;11(12):906-17.
10
Saxagliptin efficacy.
Diabetes Obes Metab. 2010 Aug;12(8):734; author reply 735. doi: 10.1111/j.1463-1326.2010.01205.x.
Zotero 插件